Racura Oncology Ltd
No trades
Fundamentals and stats
Key facts
Market capitalization—
Founded—
CEO—
Website—
About
Racura Oncology Ltd. is a Phase 3 clinical biopharmaceutical company with a dedicated mission to be at the heart of cancer care. The firm is involved in RCDS1, is a small molecule anticancer agent that primarily functions via G4-DNA & RNA binding, to potent inhibition of the important cancer growth regulator MYC. The company was founded on February 15, 2011 and is headquartered in Sydney, Australia.
Valuation
Fundamental metrics to determine fair value of the stock
Growth and Profitability
Company’s recent performance and margins
Dividends
Dividend yield, history and sustainability
No dividends
RAC has never paid dividends and has no current plans to do so.
Financial health
Financial position and solvency of the company